Workflow
Lithia & Driveway (LAD) Reports Record First Quarter Revenue of $9.2 billion, Achieves 35% Increase in Diluted Earnings Per Share, 25% Increase in Adjusted Diluted Earnings Per Share
Prnewswire· 2025-04-23 09:00
Core Insights - Lithia & Driveway reported the highest first quarter revenue in company history, with a 7% increase to $9.2 billion compared to $8.6 billion in Q1 2024 [2][21] - Diluted earnings per share increased by 35% to $7.94 from $5.89 in the same period last year [3][23] - The company announced an increased dividend of $0.55 per share, a 4% increase, to be paid on May 23, 2025 [11] Financial Performance - First quarter 2025 net income was $211 million, a 28% increase from $165 million in Q1 2024 [4][22] - Adjusted net income for Q1 2025 was $204 million, a 20% increase compared to $171 million in Q1 2024 [4][38] - The company achieved a gross profit of $1.41 billion, reflecting a 5.6% increase from $1.34 billion in the previous year [21][22] Operational Highlights - The company acquired two stores in 2025, adding an expected annualized revenue of $180 million [8][9] - New retail units increased by 3.6% on a same-store basis compared to Q1 2024 [15] - Used retail unit growth improved from -4.3% to -0.4% on a sequential same-store basis [15] Balance Sheet and Cash Flow - Lithia & Driveway ended Q1 2025 with approximately $1.4 billion in cash and cash equivalents, along with marketable securities [10] - The company repurchased approximately 403,000 shares at a weighted average price of $326 during the first quarter [12] - Net cash provided by operating activities was $322.1 million, an increase from $294 million in Q1 2024 [35] Strategic Outlook - The company emphasized its integrated ecosystem and disciplined execution of strategy, focusing on profitable growth and market share expansion [7] - Lithia & Driveway aims to deliver consistent, high-quality experiences across all channels throughout 2025 and beyond [7]
Uxin to Report Fourth Quarter and Full Year 2024 Financial Results on April 30, 2025
Prnewswire· 2025-04-23 09:00
Core Viewpoint - Uxin Limited, a leading used car retailer in China, is set to announce its financial results for Q4 and the full year 2024 on April 30, 2025, before the U.S. market opens [1]. Group 1: Financial Results Announcement - Uxin will release its financial results for the fourth quarter and full year 2024 on April 30, 2025 [1]. - The announcement will occur before the U.S. market opens [1]. Group 2: Conference Call Details - A conference call will be hosted by Uxin's management team on April 30, 2025, at 8:00 A.M. U.S. Eastern Time [2]. - Participants must complete an online registration process to receive access details for the conference call [2]. - A telephone replay of the call will be available until May 7, 2025, with specific dial-in details provided [3]. Group 3: Company Overview - Uxin is recognized for pioneering industry transformation in the used car market through advanced production and digital empowerment [4]. - The company offers high-quality vehicles and superior after-sales services, emphasizing a hassle-free transaction experience [4]. - Uxin employs an omni-channel strategy, leveraging both online platforms and offline inspection centers to serve customers nationwide [4].
Verizon's 2025 Data Breach Investigations Report: Alarming surge in cyberattacks through third-parties
Newsfilter· 2025-04-23 08:11
Core Insights - The 2025 Data Breach Investigations Report (DBIR) by Verizon Business indicates a significant rise in cyberattacks, with third-party involvement in breaches doubling to 30% and exploitation of vulnerabilities increasing by 34% [1][2][4] Cybersecurity Threat Landscape - The report analyzed over 22,000 security incidents, including 12,195 confirmed data breaches, identifying credential abuse (22%) and exploitation of vulnerabilities (20%) as the leading initial attack vectors [2][3] - Ransomware attacks have risen by 37% since last year, now present in 44% of breaches, despite a decrease in the median ransom amount paid [7] - The human element remains a significant factor in breaches, with a notable overlap between social engineering and credential abuse [7] Industry-Specific Trends - The report highlights an alarming increase in espionage-motivated attacks within the Manufacturing and Healthcare sectors, alongside persistent threats to the Education, Financial, and Retail industries [3][4] Recommendations for Businesses - Businesses are urged to adopt a multi-layered defense strategy, including strong password policies, timely patching of vulnerabilities, and comprehensive security awareness training for employees [3][4] - The median ransom payment to cybercriminals last year was US$115,000, which poses a significant financial burden for many small and medium-sized businesses (SMBs) [4][5] Overall Implications - The findings of the DBIR serve as a wake-up call for businesses to strengthen their cybersecurity posture and mitigate risks from evolving cyber threats [4][5]
Verizon's 2025 Data Breach Investigations Report: Alarming surge in cyberattacks through third-parties
GlobeNewswire News Room· 2025-04-23 08:11
BASKING RIDGE, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- Verizon Business today released its 2025 Data Breach Investigations Report (DBIR), which reveals a significant increase in cyberattacks. The report found that third-party involvement in breaches has doubled to 30%, and exploitation of vulnerabilities has surged by 34%, creating a concerning threat landscape for businesses globally. The report, which analyzed over 22,000 security incidents, including 12,195 confirmed data breaches, found that credential ...
Elanders AB: Quarterly Report January – March 2025
GlobeNewswire· 2025-04-23 08:00
First quarter 2025 Net sales amounted to MSEK 3,232 (3,268), which corresponded to an organic net sales reduction of two percent compared to the same period last year, excluding acquisitions and discontinued operations, and using unchanged exchange rates. Adjusted EBITA amounted to MSEK 133 (180), which equaled an adjusted EBITA margin of 4.1 (5.5) percent.Operating profit was impacted by one-off items of MSEK -87 (-26), which mainly referred to structural measures to meet a weaker market and over time impr ...
Reminder: Program for the publication of Yara International ASA first quarter results 2025
GlobeNewswire· 2025-04-23 08:00
Yara International ASA first quarter 2025 results will be published on Friday, 25 April 2025 at 08:00 CEST. You can follow the first-quarter results presentation online at 12:00 CEST. The presentation will be held in English. The report, presentation and webcast will be available at the above mentioned times at https://yara.com/investor-relations/latest-quarterly-report/ There will also be a conference call at 13:00 CEST the same day with an opportunity to ask questions to Yara’s management. Please use the ...
Clarivate Launches DRG Commercial Analytics 360 Enabling Medtech Companies to Advance Commercial Strategy and Execution
Prnewswire· 2025-04-23 08:00
Core Insights - Clarivate Plc has launched DRG Commercial Analytics 360, a solution aimed at enhancing commercial performance for medtech companies by providing advanced insights into customer activity and market dynamics [1][2]. Group 1: Product Features - DRG Commercial Analytics 360 integrates the Procedure Finder's search capabilities with Clarivate's extensive provider and affiliations network, delivering real-world, data-driven intelligence [2]. - The platform enables precise omnichannel targeting, seamless integration, and intelligent bundling, allowing medtech companies to make data-driven decisions that improve patient access and business outcomes [3]. - The solution offers actionable intelligence by providing tailored insights into healthcare providers, their network affiliations, and the locations where procedures are performed [5]. Group 2: Market Impact - The platform categorizes procedures by type and eliminates code-level duplication, ensuring a reliable view of procedure volume and flow across the U.S. market [5]. - It provides 360-degree market visibility through modularized claims and code groupings, supporting accurate market sizing and informed resource allocation [5]. - Clarivate's data scientists apply tailored extrapolation methodologies to derive nuanced insights across various market segments, backed by expertise in medtech and U.S. healthcare [5].
Form 8.5 (EPT/RI)-Anexo Group plc
GlobeNewswire· 2025-04-23 07:51
Key Information - The exempt principal trader involved is Investec Bank plc [1] - The offeror/offeree related to this disclosure is Anexo Group plc [1] - Investec is connected as the Financial Adviser to DBAY [1] - The dealing date is April 22, 2025 [1] Dealings by the Exempt Principal Trader - Total number of ordinary shares sold is 13,879 [3] - The highest price per unit for the sales was 59 [3] - The lowest price per unit for the sales was 51.5 [3] Other Information - There are no indemnity or option arrangements related to the relevant securities [9] - There are no agreements or understandings regarding voting rights or future acquisition/disposal of relevant securities [10] - The date of disclosure is April 23, 2025 [10]
Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS
Newsfilter· 2025-04-23 07:30
Core Viewpoint - Pharming Group N.V. has received positive final guidance from the National Institute for Health and Care Excellence (NICE) for the reimbursement and use of Joenja® (leniolisib) in treating activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in patients aged 12 and older within the NHS in England and Wales [1][2][4] Group 1: NICE Recommendation and Clinical Data - The NICE recommendation is based on comprehensive data from a Phase III clinical trial that showed significant improvements in immune deficiency and dysregulation with leniolisib compared to placebo [2][4] - The Phase III trial results indicated sustained clinical improvements during long-term treatment in an open-label extension trial [2] Group 2: Impact on Patients and Healthcare - The NICE recommendation is viewed as a significant milestone for patients with APDS, enhancing treatment options and potentially improving their quality of life [3][4] - Joenja® is now available for use and funded in England through the Innovative Medicines Fund, with expected funding in Wales within three months [4] Group 3: About Joenja® and APDS - Joenja® is the first and only targeted treatment for APDS, an oral small molecule PI3Kδ inhibitor that addresses the underlying immune system issues associated with the condition [8] - APDS is a rare primary immunodeficiency affecting approximately 1 to 2 people per million worldwide, characterized by severe recurrent infections and immune dysregulation [6][7]
BE Semiconductor Industries N.V. Announces Q1-25 Results
GlobeNewswire· 2025-04-23 07:05
Q1-25 Revenue of € 144.1 Million and Net Income of € 31.5 MillionOrders of € 131.9 Million Up 8.2% vs. Q4-24 DUIVEN, The Netherlands, April 23, 2025 (GLOBE NEWSWIRE) -- BE Semiconductor Industries N.V. (the "Company" or "Besi") (Euronext Amsterdam: BESI; OTC markets: BESIY), a leading manufacturer of assembly equipment for the semiconductor industry, today announced its results for the first quarter ended March 31, 2025. Key Highlights Revenue of € 144.1 million, down 6.1% vs. Q4-24 due primarily to lower s ...